LEVETIRACETAM TEVA ® 250 MG

Ülke: İsrail

Dil: İngilizce

Kaynak: Ministry of Health

Aktif bileşen:

LEVETIRACETAM 250 MG

Mevcut itibaren:

TEVA PHARMACEUTICAL INDUST.LTD

ATC kodu:

N03AX14

Farmasötik formu:

TABLETS

Uygulama yolu:

PER OS

Tarafından üretildi:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Terapötik grubu:

LEVETIRACETAM

Terapötik endikasyonlar:

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Yetkilendirme tarihi:

2009-09-01